Literature DB >> 3677539

Biliary excretion of intravenous [14C] omeprazole in humans.

T Lind1, T Andersson, I Skånberg, L Olbe.   

Abstract

We have studied the biliary excretion of [14C] omeprazole in humans. The study was performed in eight healthy subjects and the technique used was based on multiple marker dilution principles with double-lumen tubes placed in both the stomach and intestine. The results obtained show a 16% biliary excretion of [14C] omeprazole. These data suggest a minimal "spillover" of omeprazole from the gastric mucosa into the gastric lumen in humans. The results also agree with previous data of the fecal recovery of radiolabeled omeprazole that suggest that the fecal excretion of intravenous omeprazole in humans is entirely accounted for by biliary excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3677539     DOI: 10.1038/clpt.1987.188

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Pharmacokinetic study of omeprazole in elderly healthy volunteers.

Authors:  S Landahl; T Andersson; M Larsson; B Lernfeldt; P Lundborg; C G Regårdh; E Sixt; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

2.  Pharmacokinetics of various single intravenous and oral doses of omeprazole.

Authors:  T Andersson; C Cederberg; C G Regårdh; I Skånberg
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

4.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

Review 6.  Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.

Authors:  D McTavish; M M Buckley; R C Heel
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 7.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin.

Authors:  T Lind; C Cederberg; M Olausson; L Olbe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

10.  Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis.

Authors:  T Andersson; R Olsson; C G Regårdh; I Skånberg
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.